Shanghai, June 14, 2024, WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been named to the 2024 MSCI ESG Leaders Indexes. This marks the second consecutive year the company has been included in the indexes for its outstanding sustainability performance.

MSCI, a leading investment research firm, provides stock indexes and portfolio performance analytics to institutional investors. Its ESG Leaders Indexes are designed to represent the performance of companies with high ESG ratings relative to their sector peers. The index suite utilizes MSCI's award-winning ESG Research and ESG Ratings to identify companies that have demonstrated an ability to manage their ESG risks and opportunities and are therefore eligible for inclusion. In 2023, WuXi Biologics received an AAA rating from MSCI for outstanding performance in Key Issues of Climate Change, Corporate Governance, Talent Development, and Product Safety & Quality, on its rating scale from AAA (Leaders) to CCC (Laggards).

In line with the United Nations Sustainable Development Goals, WuXi Biologics has been making steady progress in pursuing sustainable development. In 2023, it was named to the Dow Jones Sustainability™ World Index and Emerging Markets Index, identified as a sustainability leader by S&P Global through its annual Corporate Sustainability Assessment (CSA). Since 2021, the company has been selected as a constituent company of the FTSE4Good Index Series, demonstrating strong ESG practices measured against globally recognized standards.

https://mp.weixin.qq.com/s?__biz=MzIxOTEyMTI1Nw==&mid=2651329816&idx=1&sn=191747eb1ad29c158babe3a819de2fbd&chksm=8c1ca61ebb6b2f08255d8fecdecd97f36051c86a3d012aea037a41a64193c4537b0bfe49a8d8&mpshare=1&scene=1&srcid=06140SQ7QU1YctouqUKrqlX2&sharer_shareinfo=650d07e55824e6ba197e95595d3421f8&sharer_shareinfo_first=650d07e55824e6ba197e95595d3421f8#rd